US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care business Cerenovus. According to the Financial Times, the potential deal could be worth between USD1 billion and USD1.5 billion.
Background of Cerenovus
J&J established Cerenovus as a neurovascular business unit in 2017. This was done through the acquisition of Pulsar Vascular and Neuravi. Later, it incorporated the previously acquired Codman Neuro into the unit.
Brand Strategy in 2024
In 2024, J&J downplayed the brand name of Cerenovus. It also did the same for Ethicon, DePuy Synthes, Biosense Webster, and Abiomed. These brands were put under the umbrella of Johnson & Johnson MedTech. Johnson & Johnson MedTech is the world’s second – largest medical device maker. This ranking is according to the Medtech Big 100 ranking by Medical Device Design and Outsourcing Magazine.-Fineline Info & Tech
